Onconetix, Inc. (ONCO)

Nasdaq: ONCO · Pharmaceutical Preparations · Cincinnati, OH · filing with the SEC since 2019

Full chart Alerts Compare

Grade3.3

◀ Past 2.8● Present 2.4▶ Future 4.5

2 est.

Overview Business Financials Grade Forecast Sentiment Ownership People Filings Patents Chart

The grade of Onconetix, Inc.

Nine metrics read from its own filings, by tense

Headline grade

3.3/10

◀ Past2.825% of the headline

● Present2.435% of the headline

▶ Future4.540% of the headline

All three tenses have at least two readings, so the archetype blend applies as printed.

Of the nine metrics, 7 read as filed from the record and 2 are SI estimates, each with its reasoning, its confidence and what would change it on its card.

◀ Past

What did they actually do?

2.8/1025% of the headline grade · 2 of 3 filed, 1 estimated

Surviving crises

as filed

1.1/10

Has it survived what it has been through?

20 warning events since 2019; the latest 2025-05-22.

weight 22% of this tense · 11th percentile among 497 sector filers · read for itself

From the record

Onconetix, Inc.'s filings since 2019 show 20 warning events of 3 kinds: a notice about its exchange listing (8-K item 3.01, 10 times, the latest 2025-05-22); an auditor change (8-K item 4.01, 3 times, the latest 2025-02-18); a late-report notice (Form NT 10-K or NT 10-Q, 7 times, the latest 2025-04-01) (its current reports).

A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.

Track record

as filed

5.2/10

What has it actually done, year after year?

+273.1% a year over 3 filed years; profitable in 0 of 3.

weight 45% of this tense · 52nd percentile among 323 sector filers · read for its customers

From the record

Onconetix, Inc.'s 3 filed years say what it did: revenue went from $58 thousand in fiscal 2023 to $815 thousand in fiscal 2025, up 273.1% a year; it rose in 1 of 2 years; the deepest fall was 68% from fiscal 2024 to fiscal 2025; net income was positive in 0 of 3 of those years (its annual reports).

What it rests on

revenue growth over the filed span273.1%top 1% of its family
the share of years revenue rosebottom 36% of its family
the share of filed years with a profitbottom 27% of its family
the deepest fall from a revenue peak67.7%bottom 45% of its family

A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.

Shareholder treatment

SI estimate

0.6/10

How has it treated the people who own it?

SI estimate 0.6/10, confidence 35 of 100 (one part).

weight 33% of this tense · 6th percentile among 464 sector filers · read for its shareholders

SI estimate Inferred, not read as filed

Why it is an estimate: Read from one part only, the share count over the years, which ranks in the bottom 6% of 464 in its family; fewer than two of the parts can be read: the share count over the years, and the cash returned against a positive operating cash flow or net income.
What the record cannot read: Fewer than two of the parts can be read: the share count over the years, and the cash returned against a positive operating cash flow or net income.
How it was reasoned: one part: the share count over the years, the one part on file, ranked among 464 in its family.
Confidence: 35 of 100
What would change it: A filing that carries the missing parts replaces this estimate with the filed reading.

From the record

SI estimate, not a filed reading: Onconetix, Inc.'s shareholder treatment is put at 0.6 of 10 with a confidence of 35 of 100, because read from one part only, the share count over the years, which ranks in the bottom 6% of 464 in its family; fewer than two of the parts can be read: the share count over the years, and the cash returned against a positive operating cash flow or net income. A filing that carries the missing parts replaces this estimate with the filed reading.

● Present

What are they doing right now?

2.4/1035% of the headline grade · 3 of 3 filed

Financial health

as filed

2.6/10

Is it financially healthy right now?

ROE -89%: lost 89¢ per shareholder dollar. Leverage 37%: owes 37¢ per asset dollar.

weight 45% of this tense · 26th percentile among 473 sector filers · read for itself

From the record

Return on equity: in the fiscal year ended 2025-12-31, Onconetix, Inc. lost about 89 cents for every dollar of shareholders' money, and gross profitability: its products earned about 3 cents per dollar of everything the company owns. Leverage: it owed about 37 cents per dollar of assets, and net share issuance: its share count grew 2803.0% over the year (the filed statements).

What it rests on

what it owes per dollar of assetsbottom 47% of its family
return on equitybottom 34% of its family
gross profit against assetsbottom 20% of its family
the share count against the year beforebottom 2% of its family

A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.

Industry position

as filed

4.7/10

How strong is its position in its industry?

bottom 47% of 315 in its family; net margin -1721%.

weight 22% of this tense · 47th percentile among 315 sector filers · read for its customers

From the record

Onconetix, Inc.'s standing among 315 graded names in its industry family: revenue of $815 thousand in fiscal 2025 ranks in the bottom 20% by size; a net margin of -1721% ranks in the bottom 25%; revenue growth of 273.1% a year over the last 2 filed years ranks in the top 5% (its annual reports).

What it rests on

revenue against the family$815,371bottom 20% of its family
net margin-1721.0%bottom 25% of its family
three-year revenue growth273.1%top 5% of its family

A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.

Leadership

as filed

0.6/10

What are the people in charge doing?

bottom 5% of 315 in its family for leadership; chief executive since 2026.

weight 33% of this tense · 5th percentile among 315 sector filers · read for its shareholders

From the record

Onconetix, Inc.'s leadership, from its insiders' filings and its current reports: the chief executive on the record is White, David Allan (Chief Executive Officer, as filed), filing under that title since 2026-03-27, 8 months (bottom 10% of its family); the 7 officers and directors filing in the last fifteen months have been on the record a median of 1.7 years (bottom 5%); 17 officer or director changes were reported on Form 8-K since 2023-11-13, against the 7 people in charge now (bottom 1%; fewer changes for each person reads higher) (the Form 4 record, its Form 8-K reports). Years count from a person's first filing in the SEC's data sets, which begin in 2006, so each is a floor.

What it rests on

officer and director changes on Form 8-K, against the people in charge17 in three years among 7 peoplebottom 1% of its family
the median years the people in charge have filed1.7 yearsbottom 5% of its family
the chief executive's years on the record7 monthsbottom 10% of its family

A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.

▶ Future

What are they set up to do next?

4.5/1040% of the headline grade · 2 of 3 filed, 1 estimated

Room to expand

as filed

4.2/10

How much room does it have to grow?

bottom 42% of 273 in its family for room to expand.

weight 33% of this tense · 42nd percentile among 273 sector filers · read for itself

From the record

Onconetix, Inc.'s room to grow, from the newest filed statements (fiscal 2025): cash of $5 million against no long-term debt tagged leaves 20.9% of its assets as net cash, bottom 42% of its family; cash from operations less capital spending is -1187% of revenue (bottom 22%); a gross margin of 77.6% (top 37%) (its annual report).

What it rests on

cash less debt against assets20.9%bottom 42% of its family
cash from operations less capital spending against revenue-1187.0%bottom 22% of its family
gross margin77.6%top 37% of its family

A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.

Growth drivers

as filed

4.2/10

What could actually drive growth from here?

bottom 42% of 306 in its family for growth drivers.

weight 45% of this tense · 42nd percentile among 306 sector filers · read for its customers

From the record

Onconetix, Inc.'s growth drivers, from the filed years to fiscal 2025: revenue grew 273.1% a year over the last three filed years against 273.1% over all 3, speeding up (top 40% of its family); the newest year grew -67.7% (bottom 10%); research spending grew -51.2% a year (bottom 4%); capital spending grew 145.5% a year (top 6%) (its annual reports). Onconetix, Inc. reported 4 product lines in fiscal 2025: Other Revenues at $588 thousand (72%), Product Sales at $226 thousand (28%), Development Service at $2 thousand (0%), and 1 more; 0 of 2 grew against the year before (its annual report).

What it rests on

three-year growth against the whole span+0.0 points a yeartop 40% of its family
the newest year's revenue growth-67.7%bottom 10% of its family
three-year growth of research spending-51.2%bottom 4% of its family
three-year growth of capital spending145.5%top 6% of its family

A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.

Expectations vs reality

SI estimate

5.3/10

Did its newest year beat what its own record pointed to?

SI estimate 5.3/10, confidence 20 of 100 (family median).

weight 22% of this tense · 50th percentile among 234 sector filers · read for its shareholders

SI estimate Inferred, not read as filed

Why it is an estimate: The record does not carry four filed years of revenue and two of the three parts: revenue against the prior pace, earnings against the prior average, the margin change, so the desk assumes the typical reading of its industry family, the median of 234 members with one.
What the record cannot read: The record does not carry four filed years of revenue and two of the three parts: revenue against the prior pace, earnings against the prior average, the margin change.
How it was reasoned: family median, 234 readings behind it.
Confidence: 20 of 100
What would change it: Its next annual report on file with the inputs replaces this estimate with the filed reading.

From the record

SI estimate, not a filed reading: Onconetix, Inc.'s expectations vs reality is put at 5.3 of 10 with a confidence of 20 of 100, because the record does not carry four filed years of revenue and two of the three parts: revenue against the prior pace, earnings against the prior average, the margin change, so the desk assumes the typical reading of its industry family, the median of 234 members with one. Its next annual report on file with the inputs replaces this estimate with the filed reading.

The grade is the company against its own industry, from its filings. It is not a view on the share price. How the grade is made

SI Assistanton ONCO · research, not advice